Related Experiment Video
Updated: Feb 9, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
Application of mutagen sensitivity assay in a glioma case-control study
Serap Erdal1, Bridget J McCarthy2,3, Natalia Gurule4
1Divisions of Environmental, Occupational Health Science, University of Illinois at Chicago, Chicago, IL, United States.
Abstract:
Few risk factors for glioma have been identified other than ionizing radiation. The alkylating agent acrylamide is a compound found in both occupational and the general environment and identified as one of the forty known or suspected neurocarcinogens in animal models. The mutagen sensitivity assay (MSA) has been used to indirectly show reduced DNA repair capacity upon exposure to ionizing radiation in those with glioma compared to controls. In this study, MSA was used to assess its applicability to a glioma case-control study and to test the hypothesis that subjects with glioma may have lower DNA repair capacity after exposure to selected potential human neurocarcinogens (i.e. acrylamide), compared to controls. Approximately 50 case and 50 control subjects were identified from a clinic-based study that investigated environmental risk factors for glioma, who completed an exposure survey, and had frozen immortalized lymphocytes available. A total of 50 metaphase spreads were read and reported for each participant. The association of case-control status with MSA for acrylamide, i.e. breaks per spread, was examined by multivariable logistic regression models. The mean number of breaks per slide was similar between hospital-based controls and cases. In addition, case-control status or exposure categories were not associated with the number of breaks per spread. Although the MSA has been shown as a useful molecular epidemiology tool for identifying individuals at higher risk for cancer, our data do not support the hypothesis that glioma patients have reduced DNA repair capacity in response to exposure to acrylamide. Further research is needed before the MSA is utilized in large-scale epidemiological investigations of alkylating agents.
Insights
This study investigated if glioma patients have reduced DNA repair capacity when exposed to acrylamide. The mutagen sensitivity assay (MSA) found no significant difference in DNA repair between glioma cases and controls, suggesting acrylamide is not linked to reduced repair in glioma.
Area of Science:
- Neuro-oncology
- Molecular epidemiology
- Environmental health
Background:
- Glioma risk factors are poorly understood, with ionizing radiation being a primary known factor.
- Acrylamide, a neurocarcinogen found in the environment, is a suspected risk factor for glioma.
- The mutagen sensitivity assay (MSA) can indicate reduced DNA repair capacity, potentially linked to glioma.
Purpose of the Study:
- To evaluate the mutagen sensitivity assay (MSA) for assessing DNA repair capacity in glioma.
- To test if glioma patients exhibit reduced DNA repair capacity after exposure to acrylamide.
- To explore environmental risk factors for glioma using molecular epidemiology.
Main Methods:
- A case-control study involving approximately 50 glioma patients and 50 controls.
- Utilized immortalized lymphocytes and the mutagen sensitivity assay (MSA) to measure DNA breaks after acrylamide exposure.
- Analyzed the association between case-control status, acrylamide exposure, and DNA repair capacity using logistic regression.
Main Results:
- The mean number of DNA breaks per metaphase spread was comparable between glioma cases and controls.
- No significant association was found between glioma status or acrylamide exposure categories and the number of DNA breaks.
- The mutagen sensitivity assay (MSA) did not support the hypothesis of reduced DNA repair capacity in glioma patients exposed to acrylamide.
Conclusions:
- The study's findings do not support the hypothesis that glioma patients have diminished DNA repair capacity in response to acrylamide exposure.
- The mutagen sensitivity assay (MSA) may not be suitable for investigating alkylating agent exposure in large-scale glioma epidemiological studies.
- Further research is required to validate the MSA's utility for assessing DNA repair in relation to environmental neurocarcinogens and glioma risk.
More Related Videos
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
06:13Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Related Concept Videos
01:25Mutagenicity and Carcinogenicity
01:25Control Systems: Applications
In modern vehicles, control systems manage various functions to enhance performance and safety. The steering wheel and accelerator are primary inputs in a car's control system. The...
01:20Sputum Studies II: Culture and Sensitivity
Sputum culture and sensitivity is a medical procedure used to diagnose bacterial infections in the respiratory tract and select the most appropriate antibiotics for treatment. This process involves analyzing sputum samples of thick and opaque secretions produced in the lungs and airways. These samples are collected from patients and then sent to the laboratory for analysis.
The test can identify various pathogens responsible for respiratory infections, including Streptococcus,...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:26Urine Studies II: Urine Culture and Sensitivity Test
01:13Sensitivity, Specificity, and Predicted Value
Sensitivity is the...